查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2027551

生物標記發現外包服務市場機會、成長要素、產業趨勢分析及2026-2035年預測

Biomarker Discovery Outsourcing Services Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026 - 2035
出版日期: | 出版商: Global Market Insights Inc. | 英文 140 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2025 年全球生物標記發現外包服務市場價值 151 億美元，預計到 2035 年將達到 887 億美元，年複合成長率為 19.4%。

生物標記發現外包服務市場-IMG1

生物標記發現外包服務市場的成長主要得益於研發投入的增加、對個人化醫療日益成長的關注以及高通量技術的不斷進步。生物製劑領域的蓬勃發展也推動了對專業生物標記服務需求的成長。隨著醫療保健系統向個人化治療方案轉型，對準確且檢驗的生物標記的需求變得愈發迫切。這些生物標記在現代藥物研發中至關重要，它們能夠支持患者分層、預測治療反應以及疾病監測。製藥和生物技術公司擴大將生物標記發現流程外包給擁有先進分析能力和基礎設施的專業服務供應商。這種做法有助於降低營運成本、縮短研發週期並提高效率。精準醫療在多個治療領域的日益普及，進一步鞏固了生物標記發現外包服務在全球醫療保健生態系統中的重要地位。

市場範圍
開始年份 2025
預測期 2026-2035
初始市場規模 151億美元
預測金額 887億美元
複合年成長率 19.4%

隨著各組織機構優先考慮先進的分析解決方案和數據驅動的調查方法，生物標記發現外包服務市場正在不斷發展。外包服務提供者提供涵蓋檢測、檢驗和分析的全面服務，使企業能夠更有效地管理複雜的生物數據。這一趨勢正在推動藥物發現和臨床研究領域的創新加速和成果提升。

預計到2025年，替代終點指標市場規模將達到74億美元，反映出其在生物標記發現外包服務市場中的重要地位。該領域之所以備受關注，是因為它能夠更快速地評估治療效果和疾病進展。透過提供對臨床結果的早期洞察，替代標記有助於縮短研發週期，並提高整體研究效率。法規結構內認可度的提高進一步推動了其應用，並提升了其在臨床開發過程中的重要性。

預計到2025年，基因組生物標記服務市場規模將達到67億美元，成為生物標記發現外包服務市場的主要貢獻者。複雜疾病的日益普遍推動了對基於基因組的研究和分析的需求。公共和私營部門投資的增加支持了大規模數據的產生，並加速了生物標記的識別。這些進展正在加強基因組學在現代醫療保健研發中的作用。

預計到2025年，北美生物標記發現外包服務市場佔有率將達到47.4%，這主要得益於研發活動的強勁投入和先進的醫療基礎設施。企業正日益將資源投入以生物標記為重點的研究，以最佳化藥物研發流程並支持精準醫療計畫。在降低成本的同時縮短研發週期，企業對外包服務的需求進一步推動了全部區域外包服務的採用。

目錄

第1章：調查方法

  • 研究途徑
  • 品質改進計劃
    • GMI人工智慧政策和資料完整性計劃
      • 資訊來源一致性協議
  • 調查過程和可靠性評分
    • 調查過程的組成部分
    • 評分組成部分
  • 數據收集
    • 主要來源部分列表
  • 資料探勘資訊來源
    • 付費資訊來源
      • 區域資訊來源
  • 基本估算和計算方法
    • 每種方法中基準年的計算
  • 預測模型
    • 量化市場影響分析
      • 生長參數對預測的數學影響
  • 關於調查透明度的補充信息
    • 資訊來源歸屬框架
    • 品質保證指標
    • 對信任的承諾

第2章執行摘要

第3章業界考察

  • 生態系分析
  • 影響產業的因素
    • 促進因素
      • 加大研發投入
      • 人們對個人化醫療和標靶治療的興趣日益濃厚。
      • 高通量技術的進步
      • 快速發展的生物製藥產業
    • 產業潛在風險與挑戰
      • 智慧財產權問題
      • 資料安全挑戰
    • 市場機遇
      • 拓展基於人工智慧和機器學習的藥物研發流程。
  • 成長潛力分析
  • 監理情勢（基於初步調查）
  • 科技趨勢
    • 當前技術趨勢
      • 高通量蛋白質體學和多體學整合
      • 臨床級生物標記檢驗工作流程
    • 新興技術
      • 人工智慧驅動的生物標記發現與數據整合
      • 下一代多奈米顆粒蛋白質體學
  • 未來市場趨勢（基於初步研究）
  • 人工智慧和生成式人工智慧對市場的影響（基於初步研究）
  • 波特的分析
  • PESTEL 分析

第4章 競爭情勢

  • 介紹
  • 企業市佔率分析
    • 世界
    • 北美洲
    • 歐洲
    • 亞太地區
  • 企業矩陣分析
  • 主要市場公司的競爭分析
  • 競爭定位矩陣
  • 主要進展
    • 併購
    • 夥伴關係與合作
    • 新產品發布
    • 業務拓展計劃

第5章 市場估計與預測：依類型分類，2022-2035年

  • 預測性生物標記
  • 預後生物標記
  • 安全生物標記
  • 替代終點
  • 其他類型

第6章 市場估計與預測：依服務業分類，2022-2035年

  • 基因組生物標記服務
  • 蛋白質體學生物標記服務
  • 生物資訊學生物標記服務
  • 其他生物標記服務

第7章 市場估計與預測：依治療領域分類，2022-2035年

  • 腫瘤學
  • 循環系統
  • 神經病學
  • 自體免疫疾病
  • 其他治療領域

第8章 市場估算與預測：依最終用途分類，2022-2035年

  • 製藥公司
  • 生技公司
  • 其他最終用戶

第9章 市場估計與預測：依地區分類，2022-2035年

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第10章：公司簡介

  • 世界公司
    • Almac Group Limited
    • Bio-Rad Laboratories
    • Crown Bioscience
    • Evotec
    • Frontage Labs
    • ICON
    • Parexel International Corporation
    • Sino Biological
  • 當地公司
    • Biomcare ApS
    • Emery Pharma
    • RayBiotech
    • REPROCELL
    • Selvita
    • Svar Life Science
  • 新興企業
    • Excelra
    • Sapient Bioanalytics
簡介目錄
Product Code: 7722

The Global Biomarker Discovery Outsourcing Services Market was valued at USD 15.1 billion in 2025 and is estimated to grow at a CAGR of 19.4% to reach USD 88.7 billion by 2035.

Biomarker Discovery Outsourcing Services Market - IMG1

Growth in the biomarker discovery outsourcing services market is driven by rising investments in research and development, growing focus on personalized medicine, and continuous advancements in high-throughput technologies. The expanding biologics sector is also contributing to increased demand for specialized biomarker services. As healthcare systems move toward individualized treatment approaches, the need for accurate and validated biomarkers is becoming more critical. These biomarkers support patient stratification, treatment response prediction, and disease monitoring, making them essential for modern drug development. Pharmaceutical and biotechnology companies are increasingly outsourcing biomarker discovery processes to specialized service providers that offer advanced analytical capabilities and infrastructure. This approach helps reduce operational costs, accelerate development timelines, and improve efficiency. The growing adoption of precision medicine across multiple therapeutic areas is further strengthening the role of biomarker discovery outsourcing services in the global healthcare ecosystem.

Market Scope
Start Year2025
Forecast Year2026-2035
Start Value$15.1 Billion
Forecast Value$88.7 Billion
CAGR19.4%

The biomarker discovery outsourcing services market is evolving as organizations prioritize advanced analytical solutions and data-driven research methodologies. Outsourcing providers are offering comprehensive capabilities that cover detection, validation, and analysis, enabling companies to manage complex biological data more effectively. This trend is supporting faster innovation and improved outcomes in drug development and clinical research.

The surrogate endpoints segment generated USD 7.4 billion in 2025, reflecting its significant role in the biomarker discovery outsourcing services market. This segment is gaining traction due to its ability to support faster evaluation of treatment effectiveness and disease progression. By enabling earlier insights into clinical outcomes, surrogate markers help reduce development timelines and improve overall research efficiency. Their growing acceptance within regulatory frameworks is further supporting adoption and enhancing their importance in clinical development processes.

The genomics biomarker services segment accounted for USD 6.7 billion in 2025, making it a leading contributor to the biomarker discovery outsourcing services market. The increasing prevalence of complex health conditions is driving demand for genomic-based research and analysis. Rising investments from both public and private sectors are supporting large-scale data generation and accelerating biomarker identification. These advancements are strengthening the role of genomics in modern healthcare research and development.

North America Biomarker Discovery Outsourcing Services Market held a 47.4% share in 2025, supported by strong investment in research and development activities and the presence of advanced healthcare infrastructure. Companies are increasingly allocating resources to biomarker-focused research to enhance drug discovery processes and support precision medicine initiatives. The need to balance cost efficiency with accelerated development timelines is further encouraging the adoption of outsourcing services across the region.

Key companies operating in the Global Biomarker Discovery Outsourcing Services Market include Almac Group Limited, Bio Rad Laboratories, Crown Bioscience, Evotec, Frontage Labs, ICON, Parexel International Corporation, Sino Biological, Biomcare ApS, Emery Pharma, RayBiotech, REPROCELL, Selvita, Svar Life Science, Excelra, and Sapient Bioanalytics. Companies in the biomarker discovery outsourcing services market are implementing strategic initiatives to strengthen their competitive position and expand their global presence. A strong emphasis is placed on enhancing technological capabilities, particularly in genomics, proteomics, and data analytics, to deliver high-quality research outcomes. Organizations are investing in advanced infrastructure and expanding service portfolios to meet evolving client requirements. Strategic partnerships and collaborations with pharmaceutical and biotechnology firms are helping companies improve market reach and accelerate innovation. Firms are also focusing on improving operational efficiency and reducing turnaround times to attract more clients.

Table of Contents

Chapter 1 Research Methodology

  • 1.1 Research approach
  • 1.2 Quality commitments
    • 1.2.1 GMI AI policy & data integrity commitment
      • 1.2.1.1 Source consistency protocol
  • 1.3 Research trail & confidence scoring
    • 1.3.1 Research trail components
    • 1.3.2 Scoring components
  • 1.4 Data collection
    • 1.4.1 Partial list of primary sources
  • 1.5 Data mining sources
    • 1.5.1 Paid sources
      • 1.5.1.1 Sources, by region
  • 1.6 Base estimates and calculations
    • 1.6.1 Base year calculation for any one approach
  • 1.7 Forecast model
    • 1.7.1 Quantified market impact analysis
      • 1.7.1.1 Mathematical impact of growth parameters on forecast
  • 1.8 Research transparency addendum
    • 1.8.1 Source attribution framework
    • 1.8.2 Quality assurance metrics
    • 1.8.3 Our commitment to trust

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis
  • 2.2 Key market trends
    • 2.2.1 Type trends
    • 2.2.2 Service trends
    • 2.2.3 Therapeutic area trends
    • 2.2.4 End use trends
    • 2.2.5 Regional trends
  • 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising investments in research and development
      • 3.2.1.2 Increasing focus on personalized medicine and targeted therapies
      • 3.2.1.3 Advancements in high-throughput technologies
      • 3.2.1.4 Booming biologics industry
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Intellectual property concerns
      • 3.2.2.2 Issues related to data security
    • 3.2.3 Market opportunities
      • 3.2.3.1 Expansion of AI and machine-learning-based discovery pipelines
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape (Driven by primary research)
    • 3.4.1 North America
    • 3.4.2 Europe
    • 3.4.3 Asia Pacific
    • 3.4.4 Latin America
    • 3.4.5 Middle East and Africa
  • 3.5 Technology landscape
    • 3.5.1 Current technological trends
      • 3.5.1.1 High-throughput proteomics and multi-omics integration
      • 3.5.1.2 Clinical-grade biomarker validation workflows
    • 3.5.2 Emerging technologies
      • 3.5.2.1 AI-driven biomarker discovery and data integration
      • 3.5.2.2 Next-generation multi-nanoparticle proteomics
  • 3.6 Future market trends (Driven by primary research)
  • 3.7 Impact of AI and Generative AI on the market (Driven by Primary Research)
  • 3.8 Porter’s analysis
  • 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

  • 4.1 Introduction
  • 4.2 Company market share analysis
    • 4.2.1 Global
    • 4.2.2 North America
    • 4.2.3 Europe
    • 4.2.4 Asia Pacific
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Key developments
    • 4.6.1 Mergers and acquisitions
    • 4.6.2 Partnerships and collaborations
    • 4.6.3 New product launches
    • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Type, 2022-2035 ($ Mn)

  • 5.1 Key trends
  • 5.2 Predictive biomarkers
  • 5.3 Prognostic biomarkers
  • 5.4 Safety biomarkers
  • 5.5 Surrogate endpoints
  • 5.6 Other types

Chapter 6 Market Estimates and Forecast, By Service, 2022-2035 ($ Mn)

  • 6.1 Key trends
  • 6.2 Genomics biomarker services
  • 6.3 Proteomics biomarker services
  • 6.4 Bioinformatics biomarker services
  • 6.5 Other biomarker services

Chapter 7 Market Estimates and Forecast, By Therapeutic Area, 2022-2035 ($ Mn)

  • 7.1 Key trends
  • 7.2 Oncology
  • 7.3 Cardiology
  • 7.4 Neurology
  • 7.5 Autoimmune diseases
  • 7.6 Other therapeutic areas

Chapter 8 Market Estimates and Forecast, By End Use, 2022-2035 ($ Mn)

  • 8.1 Key trends
  • 8.2 Pharmaceutical companies
  • 8.3 Biotechnology companies
  • 8.4 Other end users

Chapter 9 Market Estimates and Forecast, By Region, 2022-2035 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 Global players
    • 10.1.1 Almac Group Limited
    • 10.1.2 Bio-Rad Laboratories
    • 10.1.3 Crown Bioscience
    • 10.1.4 Evotec
    • 10.1.5 Frontage Labs
    • 10.1.6 ICON
    • 10.1.7 Parexel International Corporation
    • 10.1.8 Sino Biological
  • 10.2 Regional players
    • 10.2.1 Biomcare ApS
    • 10.2.2 Emery Pharma
    • 10.2.3 RayBiotech
    • 10.2.4 REPROCELL
    • 10.2.5 Selvita
    • 10.2.6 Svar Life Science
  • 10.3 Emerging players
    • 10.3.1 Excelra
    • 10.3.2 Sapient Bioanalytics